参考文献: [1] Kodandaram Pillarisetti, Suzanne Edavettal, Mark Mendonça, et al; A T-cell–redirecting bispecific G-protein–coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma. Blood 2020; 135 (15): 1232–1243. [2] DOI: 10.1200/JCO.2021.39.15_suppl.LBA2 Jour...
TECVAYLI®, which is administered subcutaneously, was the first bispecific antibody targeting B-cell maturation antigen (BCMA) on multiple myeloma cells and CD3 on T-cells to activate an immune response.2TECVAYLI® wasap...
Another bispecific antibody,talquetamab, also gained accelerated approval for adults with relapsed or refractorymultiple myelomawho have received at least 4 prior therapies, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. It is a bispecific humanized mono...
[5]Chari A, Minnema MC, Berdeja JG,et al. Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma. N Engl J Med. 2022 Dec 15;387(24):2232-2244. [6]
FDA Approves Second Bispecific Antibody for Diffuse Large B-cell Lymphoma. Formulary Watch. 16. 06. 2023. Specialty Drug Pipeline Monthly Update: July 2023. Prime Therapeutics. 24. 07. 2023. Dunleavy, K. Pfizer's approval st...
Tecvayli, a BCMA-directed bispecific antibody, is the first drug of its class to be approved for multiple myeloma. The approval comes with a boxed warning for cytokine release syndrome (a condition where the immune system reacts more aggressively than it shoul...
On Monday, the FDA granted accelerated approval to elranatamab-bcmm (Elrexfio, Pfizer, Inc.), a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, for adults with relapsed or refractory multiple myeloma who have received at least...
ELREXFIO is a subcutaneously delivered B-cell maturation antigen (BCMA)-CD3-directed bispecific antibody (BsAb) immunotherapy that binds to BCMA on myeloma cells and CD3 on T-cells, bringing them together and activating the T-cells to kill myeloma cells. “ELR...
按照Talvey递增剂量方案给药后,患者应住院48小时。 ™(talquetamab-tgvs), a first-in-class bispecific therapy for the treatment of patients with heavily pretreated multiple myeloma. Janssen. News release. August 10, 2023.
英文标题:A novel tri-specific T cell engager targeting BCMA and GPRC5D for treatment of multiple myeloma 中文标题:一种新型三特异性T细胞接合剂,靶向BCMA和GPRC5D,用于治疗多发性骨髓瘤 讲者:S. Han 嘉和生物 摘要号:LB129 / 17 英文标题...